BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Buy at Jefferies Financial Group

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was upgraded by equities research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, FlyOnTheWall reports. Other research analysts have also issued research reports about the company. StockNews.com lowered BioCryst Pharmaceuticals from a […]

Related Keywords

United States ,Switzerland ,America ,Swiss ,Machelle Sanders ,Biocryst Pharmaceuticals ,Biocryst Pharmaceuticals Stock ,Needham Company ,Artisan Partners Limited Partnership ,Proshare Advisors ,International Assets Investment Management ,Alphacentric Advisors ,Nasdaq ,Analyst Recommendations For Biocryst Pharmaceuticals ,Jefferies Financial Group ,News Ratings For Biocryst Pharmaceuticals Daily ,Swiss National Bank ,Institutional Trading Of Biocryst Pharmaceuticals ,Biocryst Pharmaceuticals Inc ,Get Free Report ,Cryst Pharmaceuticals ,Director Machelle Sanders ,Share Advisors ,Assets Investment Management ,Partners Limited Partnership ,National Bank ,Centric Advisors ,Biocryst Pharmaceuticals Daily ,Nasdaq Bcrx ,Bcrx ,Medical ,09058v10 ,Upgrade ,Jefferies Financial Group Inc ,